ZA964822B - Antigenic group b streptococcus type ii and type iii polysaccharide- fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof - Google Patents

Antigenic group b streptococcus type ii and type iii polysaccharide- fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof

Info

Publication number
ZA964822B
ZA964822B ZA964822A ZA964822A ZA964822B ZA 964822 B ZA964822 B ZA 964822B ZA 964822 A ZA964822 A ZA 964822A ZA 964822 A ZA964822 A ZA 964822A ZA 964822 B ZA964822 B ZA 964822B
Authority
ZA
South Africa
Prior art keywords
type
fragments
anhydro
terminal structure
conjugate vaccine
Prior art date
Application number
ZA964822A
Other languages
English (en)
Inventor
Francis Michon
Catherine Dong
Joseph Y Tai
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of ZA964822B publication Critical patent/ZA964822B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA964822A 1995-06-07 1996-06-07 Antigenic group b streptococcus type ii and type iii polysaccharide- fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof ZA964822B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/481,883 US6284884B1 (en) 1995-06-07 1995-06-07 Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof

Publications (1)

Publication Number Publication Date
ZA964822B true ZA964822B (en) 1997-01-07

Family

ID=23913768

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964822A ZA964822B (en) 1995-06-07 1996-06-07 Antigenic group b streptococcus type ii and type iii polysaccharide- fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof

Country Status (15)

Country Link
US (3) US6284884B1 (ja)
EP (1) EP0830380B1 (ja)
JP (1) JP4001625B2 (ja)
KR (1) KR100431236B1 (ja)
AT (1) ATE236194T1 (ja)
AU (1) AU706479B2 (ja)
CA (1) CA2223080C (ja)
DE (1) DE69627149T2 (ja)
ES (1) ES2200067T3 (ja)
HU (1) HUP9900919A3 (ja)
IL (3) IL136125A (ja)
NO (1) NO975546L (ja)
PL (1) PL187822B1 (ja)
WO (1) WO1996040795A1 (ja)
ZA (1) ZA964822B (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311550A2 (en) * 2000-08-22 2003-05-21 National Research Council Of Canada Synthesis of complex carbohydrates
EP2277894A1 (en) * 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
EP1551357B1 (en) * 2002-09-13 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus vaccine
ES2317043T3 (es) * 2003-06-23 2009-04-16 Baxter International Inc. Proteinas portadoras para vacunas.
ES2505695T3 (es) * 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US20090136547A1 (en) * 2005-08-24 2009-05-28 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
PL2054431T3 (pl) * 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
US20110038879A1 (en) * 2006-10-30 2011-02-17 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
CA2698157C (en) * 2007-09-11 2016-10-11 University Of Guelph Novel polysaccharide immunogens from clostridium difficile
CN101969992B (zh) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57突变型抗原和gas57抗体
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
CA2756170C (en) 2009-03-23 2019-04-02 The Brigham And Women's Hospital, Inc. Glycoconjugate vaccines
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
JP6170932B2 (ja) 2011-11-07 2017-07-26 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
CA2883481A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
WO2014158963A1 (en) 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
ES2756526T3 (es) 2013-07-11 2020-04-27 Novartis Ag Modificaciones de proteínas quimioenzimáticas específicas para lisina utilizando transglutaminasa microbiana
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
BR112022023261A2 (pt) 2020-06-12 2022-12-27 Glaxosmithkline Biologicals Sa Imunização bacteriana usando vacina de nanopartícula
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352773A (en) 1964-09-16 1967-11-14 Gillette Res Inst Inc Method of degrading polysaccharides using light radiation and a watersoluble metal or nitrogen base salt of nitrous or hyponitric acid
US3922260A (en) 1973-08-24 1975-11-25 Quintin P Peniston Process for depolymerization of chitosan
US4207414A (en) 1978-08-16 1980-06-10 President And Fellows Of Harvard College Polysaccharide antigens
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4439422A (en) 1980-01-02 1984-03-27 Research Corporation Group B Streptococcus antigens and vaccines
US4413057A (en) 1980-04-14 1983-11-01 Merck & Co., Inc. Group B streptococcal capsular polysaccharides
PT72812B (en) 1980-04-14 1983-02-16 Merck & Co Inc Process for preparing group b streptococcal capsular polysccha-rides
US4438261A (en) 1980-05-19 1984-03-20 Riker Laboratories, Inc. Anticoagulant substance
US4367222A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immune globulin specific to Group B streptococci
US4356263A (en) 1980-06-09 1982-10-26 President And Fellows Of Harvard College Method of making a polysaccharide vaccine
US4367221A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Immunization against Group B streptococci
US4367223A (en) 1980-06-09 1983-01-04 President And Fellows Of Harvard College Vaccine against Group B streptococci
US4284537A (en) 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4757134A (en) 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein
EP0175261B1 (en) 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
JP2754000B2 (ja) 1986-04-16 1998-05-20 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド 細菌抗原、抗体、ワクチン及びその製造方法
US5302386A (en) 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
WO1989000583A1 (en) 1987-07-17 1989-01-26 Xoma Corporation Improved immunotoxin therapies utilizing purified ricin a-chain species
JP2871822B2 (ja) 1989-08-29 1999-03-17 玉造株式会社 末端に２，５―アンヒドロマンニトール基または２，５―アンヒドロマンノース基を有するキチン・キトサンオリゴマーおよびその製造方法
IL95578A (en) 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
AU6538490A (en) 1989-09-18 1991-04-18 Brigham And Women's Hospital Enzymatic generation and recovery of group b streptococcus type iii capsular oligosaccharides
RO111416B1 (ro) 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0577723A1 (en) 1991-03-29 1994-01-12 FAULMANN, Ervin METHOD FOR PRODUCTION OF AN IgA BINDING PROTEIN DERIVED FROM GROUP B STREPTOCOCCI
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
US5352588A (en) 1991-12-24 1994-10-04 Rockefeller University Streptococcal immunoglobulin a binding protein encoded by emmL2.2
WO1993015217A1 (en) * 1992-02-04 1993-08-05 Quidel Corporation Simplified extraction method for bacterial antigens using dried reagents
ZA937034B (en) 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
IL107458A0 (en) 1992-11-02 1994-02-27 Gen Hospital Corp Conjugate vaccine against group b streptococcus
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5595740A (en) * 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
EP1058331A4 (en) 1998-12-22 2004-07-07 Mitsubishi Electric Corp ELECTROLYTIC SOLUTION FOR CELLS AND CELLS MADE WITH SUCH A SOLUTION

Also Published As

Publication number Publication date
ES2200067T3 (es) 2004-03-01
PL323822A1 (en) 1998-04-27
US6372222B1 (en) 2002-04-16
HUP9900919A3 (en) 2000-04-28
WO1996040795A1 (en) 1996-12-19
AU6095396A (en) 1996-12-30
CA2223080A1 (en) 1996-12-19
DE69627149D1 (de) 2003-05-08
EP0830380B1 (en) 2003-04-02
JP4001625B2 (ja) 2007-10-31
KR19990022747A (ko) 1999-03-25
US6284884B1 (en) 2001-09-04
NO975546D0 (no) 1997-12-02
JPH11507964A (ja) 1999-07-13
NO975546L (no) 1998-02-06
IL118603A0 (en) 1996-10-16
IL136125A0 (en) 2001-05-20
ATE236194T1 (de) 2003-04-15
DE69627149T2 (de) 2003-12-04
US6602508B2 (en) 2003-08-05
KR100431236B1 (ko) 2004-09-16
AU706479B2 (en) 1999-06-17
IL118603A (en) 2000-12-06
PL187822B1 (pl) 2004-10-29
IL136125A (en) 2006-08-01
CA2223080C (en) 2007-03-20
HUP9900919A2 (hu) 1999-06-28
EP0830380A1 (en) 1998-03-25
US20020031526A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
IL118603A (en) Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
IL115047A0 (en) Pneumococcal polysaccharide - recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections.
BR0009163A (pt) Vacina
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
GR3034916T3 (en) Group a streptococcal polysaccharide immunogenic compositions and methods
ES2179261T3 (es) Vacuna a base de streptococcus equi.
NO975547L (no) Vaksiner med modifiserte meningokokk/polysakkarid-konjugater
PL332540A1 (en) Method of inducing active immunity using a vaccine conjugate
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
PL286898A1 (en) Method of obtaining a conjugated vaccine against streptococcus of b group, method of obtaining a recombined molecule and method of obtaining a protein of atreptococcus o b group
ES2131066T3 (es) Vacuna de conjugacion de oligosacarido con adhesina para hi(haemophilus influenzae).
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
Lempert et al. Isolation of type-nonspecific protein antigens of group B Streptococcus.